Cited 0 times in
Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남효석 | - |
dc.date.accessioned | 2024-02-15T06:55:26Z | - |
dc.date.available | 2024-02-15T06:55:26Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198073 | - |
dc.description.abstract | Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke. Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction ≥50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events. Results Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2±34.7 mg/dL in the ROS10/EZT10 group and 131.0±33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352–2.795]; P= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (P=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (P<0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (P=0.0091). The adverse event rates did not differ between the two groups. Conclusion Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction ≥50% and 80% had an LDL-C <70 mg/dL at 90 days. © 2023 Korean Stroke Society. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Stroke Society | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | Keun-Sik Hong | - |
dc.contributor.googleauthor | Oh Young Bang | - |
dc.contributor.googleauthor | Jong-Ho Park | - |
dc.contributor.googleauthor | Jin-Man Jung | - |
dc.contributor.googleauthor | Sang-Hun Lee | - |
dc.contributor.googleauthor | Tae-Jin Song | - |
dc.contributor.googleauthor | Hyo Suk Nam | - |
dc.contributor.googleauthor | Hee-Kwon Park | - |
dc.contributor.googleauthor | Keun-Hwa Jung | - |
dc.contributor.googleauthor | Sung Hyuk Heo | - |
dc.contributor.googleauthor | Jaseong Koo | - |
dc.contributor.googleauthor | Kyung-Ho Yu | - |
dc.contributor.googleauthor | Kwang-Yeol Park | - |
dc.contributor.googleauthor | Chi Kyung Kim | - |
dc.contributor.googleauthor | Hong-Kyun Park | - |
dc.contributor.googleauthor | Jiyoon Lee | - |
dc.contributor.googleauthor | Juneyoung Lee | - |
dc.contributor.googleauthor | Woo-Keun Seo | - |
dc.identifier.doi | 10.5853/jos.2022.02957 | - |
dc.contributor.localId | A01273 | - |
dc.relation.journalcode | J01758 | - |
dc.identifier.eissn | 2287-6405 | - |
dc.identifier.pmid | 37032475 | - |
dc.subject.keyword | Ezetimibe | - |
dc.subject.keyword | LDL cholesterol | - |
dc.subject.keyword | Rosuvastatin | - |
dc.subject.keyword | Stroke | - |
dc.subject.keyword | Target goal | - |
dc.contributor.alternativeName | Nam, Hyo Suk | - |
dc.contributor.affiliatedAuthor | 남효석 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 242 | - |
dc.citation.endPage | 250 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, Vol.25(2) : 242-250, 2023-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.